UNSPSC 51181901: Choriogonadotropin alfa or chorionic gonadotropin

This classification denotes a therapeutic gonadotropin with the molecular formula C1105H1770N318O336S26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6413W06WR3, more generally known as chorionic gonadotropin. European Medicines Agency schedules chorionic gonadotropin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12481MIG. The term CHORIOGONADOTROPIN ALFA is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 11, no. 11997, list 37. SMILES: NONE.

UNSPSC 51181901 Choriogonadotropin alfa or chorionic gonadotropin is a Commodity code covering hormonal pharmaceuticals used in fertility treatment and diagnostic applications that state and local health agencies, departments, and cooperative purchasing consortia procure through multi-source pharmaceutical frameworks. State and local governments buy this product as part of broader generic and brand pharmaceutical procurement vehicles managed through cooperative purchasing alliances and state health department supply agreements. The solicitations under this code reflect demand from state medicaid programs, institutional health facilities, and county health departments that require reliable supply contracts for fertility and endocrinology treatments through established pharmaceutical distribution channels.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and mandates cGMP certification, Drug Supply Chain Security Act compliance, and pricing submission in flat-price, net-price, or WAC-minus formats. Contract term is two years for new vendors with optional extensions, effective July 1, 2026, with evaluated criteria weighted heavily toward price competitiveness (75 percent) and compliance with administrative data and EDI requirements. The opportunity spans a multi-state purchasing consortium active in the upper Midwest and Pacific Northwest, typical of how state and local buyers aggregate pharmaceutical demand through cooperative vehicles to secure volume pricing and streamlined vendor management across health system networks.